Literature DB >> 33106921

Noscapine alleviates cerebral damage in ischemia-reperfusion injury in rats.

Manisha Kawadkar1, Avinash S Mandloi1, Vidhu Saxena1, Chetana Tamadaddi2, Chandan Sahi2, Vipin V Dhote3.   

Abstract

With high unmet medical needs, stroke remains an intensely focused research area. Although noscapine is a neuroprotective agent, its mechanism of action in ischemic-reperfusion (I-R) injury is yet to be ascertained. We investigated the effect of noscapine on the molecular mechanisms of cell damage using yeast, and its neuroprotection on cerebral I-R injury in rats. Yeast, both wild-type and Δtrx2 strains, was evaluated for cell growth and viability, and oxidative stress to assess the noscapine effect at 8, 10, 12, and 20 μg/ml concentrations. The neuroprotective activity of noscapine (5 and 10 mg/kg; po for 8 days) was investigated in rats using middle cerebral artery occlusion-induced I-R injury. Infarct volume, neurological deficit, oxidative stress, myeloperoxidase activity, and histological alterations were determined in I-R rats. In vitro yeast assays exhibited significant antioxidant activity and enhanced cell tolerance against oxidative stress after noscapine treatment. Similarly, noscapine pretreatment significantly reduced infarct volume and edema in the brain. The neurological deficit was decreased and oxidative stress biomarkers, superoxide dismutase activity and glutathione levels, were significantly increased while lipid peroxidation showed significant decrease in comparison to vehicle-treated I-R rats. Myeloperoxidase activity, an indicator of inflammation, was also reduced significantly in treated rats; histological changes were attenuated with noscapine. The study demonstrates the protective effect of noscapine in yeast and I-R rats by improving cell viability and attenuating neuronal damage, respectively. This protective activity of noscapine could be attributed to potent free radical scavenging and inhibition of inflammation in cerebral ischemia-reperfusion injury.

Entities:  

Keywords:  Antioxidant; Inflammation; Ischemia-reperfusion injury; Middle cerebral artery occlusion; Yeast

Year:  2020        PMID: 33106921     DOI: 10.1007/s00210-020-02005-x

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  39 in total

Review 1.  Preconditioning and tolerance against cerebral ischaemia: from experimental strategies to clinical use.

Authors:  Ulrich Dirnagl; Kyra Becker; Andreas Meisel
Journal:  Lancet Neurol       Date:  2009-04       Impact factor: 44.182

Review 2.  Involvement of bradykinin in brain edema development after ischemic stroke.

Authors:  Marina Dobrivojević; Katarina Špiranec; Aleksandra Sinđić
Journal:  Pflugers Arch       Date:  2014-04-23       Impact factor: 3.657

Review 3.  Pathophysiology of ischaemia-reperfusion injury.

Authors:  D L Carden; D N Granger
Journal:  J Pathol       Date:  2000-02       Impact factor: 7.996

Review 4.  Drug treatment of acute ischemic stroke.

Authors:  Sameer Bansal; Kiranpal S Sangha; Pooja Khatri
Journal:  Am J Cardiovasc Drugs       Date:  2013-02       Impact factor: 3.571

Review 5.  Targeting ischemic brain injury with intravenous immunoglobulin.

Authors:  Thiruma V Arumugam; Pradeep K Selvaraj; Trent M Woodruff; Mark P Mattson
Journal:  Expert Opin Ther Targets       Date:  2008-01       Impact factor: 6.902

Review 6.  Look into brain energy crisis and membrane pathophysiology in ischemia and reperfusion.

Authors:  Maria Chomova; Ingrid Zitnanova
Journal:  Stress       Date:  2016-04-19       Impact factor: 3.493

7.  Antioxidant protection of resveratrol and catechin in Saccharomyces cerevisiae.

Authors:  Caroline Dani; Diego Bonatto; Mirian Salvador; Marcos D Pereira; João A P Henriques; Elis Eleutherio
Journal:  J Agric Food Chem       Date:  2008-05-20       Impact factor: 5.279

8.  LF 16-0687 Ms, a bradykinin B2 receptor antagonist, reduces ischemic brain injury in a murine model of transient focal cerebral ischemia.

Authors:  Li Ding-Zhou; Isabelle Margaill; Bruno Palmier; Didier Pruneau; Michel Plotkine; Catherine Marchand-Verrecchia
Journal:  Br J Pharmacol       Date:  2003-08       Impact factor: 8.739

9.  A central role for TOR signalling in a yeast model for juvenile CLN3 disease.

Authors:  Michael E Bond; Rachel Brown; Charalampos Rallis; Jürg Bähler; Sara E Mole
Journal:  Microb Cell       Date:  2015-11-11

10.  Yeast screening platform identifies FDA-approved drugs that reduce Aβ oligomerization.

Authors:  Triana Amen; Daniel Kaganovich
Journal:  Microb Cell       Date:  2016-03-03
View more
  2 in total

1.  The Ameliorative Role of Acacia senegal Gum against the Oxidative Stress and Genotoxicity Induced by the Radiographic Contrast Medium (Ioxitalamate) in Albino Rats.

Authors:  Islam El-Garawani; Sobhy Hassab El-Nabi; Ahmed El Kattan; Azza Sallam; Sabha Elballat; Shaimaa Abou-Ghanima; Islam H El Azab; Hesham R El-Seedi; Shaden A M Khalifa; Sawsan El-Shamy
Journal:  Antioxidants (Basel)       Date:  2021-02-02

2.  Attenuation Effect of Salvianolic Acid B on Testicular Ischemia-Reperfusion Injury in Rats.

Authors:  Si-Ming Wei; Yu-Min Huang
Journal:  Oxid Med Cell Longev       Date:  2022-01-13       Impact factor: 6.543

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.